This is an observational research study to find out if there is a difference in the way children with moderate or severe hemophilia A, treated on two different types of factor replacement, form a clot and also evaluate if they develop tiny bleeds within the joint and subsequently early joint changes when receiving extended half-life factor VIII.
Participants with moderate or severe HA who are on prophylaxis with either weekly, biweekly, or every 4-weeks emicizumab or weekly efanesoctocog alfa for at least 2 months.
>6 months of age
Participants with active FVIII inhibitor (>0.5 BU/mL)
Presence of an additional bleeding disorder other than hemophilia A
University of Texas Southwestern Medical Center
Lead sponsor
Sanofi
Collaborator